Released on May 1, 2012
Effective May 1, the blood thinning medication Pradax has been added to the Saskatchewan Formulary's Exception Drug Status program for those patients with atrial fibrillation (a form of irregular heart beat) who meet specific criteria.
The drug is prescribed for patients who require blood thinners to prevent strokes or blood clots and does not require frequent blood test monitoring.
"Adding this drug coverage for eligible patients is another example of how we are putting the patient first," Health Minister Don McMorris said. "This is something that patients, physicians and pharmacists have been asking for and we are pleased to provide this coverage. This is another demonstration of health system partners working together and listening to patients, to improve the health of Saskatchewan people."
The average full monthly cost of a Pradax prescription is $130.
Saskatchewan patients who require Pradax to treat their medical condition may now realize significant cost savings if they are eligible for Exception Drug Status coverage.
Patients' physicians or pharmacists will need to apply for Exception Drug Status to determine if the eligibility requirements for coverage have been met. The amount a patient pays per prescription will be determined by their level of coverage under the Saskatchewan Drug Plan.
Saskatchewan participated in a pan-Canadian negotiation process to obtain the best value for this product.
It is estimated 1,600 patients in Saskatchewan are currently receiving prescriptions for Pradax. The anticipated cost of adding this drug is $1.5-$2 million for 2012-13.
If you have questions regarding the Exception Drug Status, please contact the Drug Plan and Extended Benefits Branch at 306-787-8744 or 1-800-667-7581.
-30-
For more information, contact:
Tyler McMurchy
Health
Regina
Phone: 306-787-4083
Email: tmcmurchy@health.gov.sk.ca